RECRUITING

Cerebrospinal Fluid Biomarkers for Brain Tumors

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.

Official Title

Cerebrospinal Fluid Biomarkers for Brain Tumors

Quick Facts

Study Start:2021-01-14

Study Completion:2025-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04692324

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures * Subjects must be 18 years of age or older	* Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study * Pregnant women or women who may be pregnant are specifically excluded from study participation * Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available * Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded * Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded * Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access

Inclusion Criteria

Exclusion Criteria

* Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures
* Subjects must be 18 years of age or older

* Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study
* Pregnant women or women who may be pregnant are specifically excluded from study participation
* Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available
* Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded
* Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded
* Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access

Contacts and Locations

Study Contact

Clinical Trials Referral Office

CONTACT

855-776-0015

mayocliniccancerstudies@mayo.edu

Principal Investigator

Terence C. Burns, M.D., Ph.D.

PRINCIPAL_INVESTIGATOR

Mayo Clinic in Rochester

Study Locations (Sites)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Terence C. Burns, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-01-14

Study Completion Date2025-12-31

Study Record Updates

Study Start Date2021-01-14

Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

Central Nervous System Neoplasm